Search research articles
Contact Us
Filters
Showing results (421-430 of 753) with videos related to
Page
of 76
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 1994
Timing of baseline quality of life assessment in an international adjuvant breast cancer trial: its effect on patient self-estimation. The International Breast Cancer Study Group
C Hürny, J Bernhard, A Coates, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 26, 1998
Pre-operative chemotherapy and radiotherapy in breast cancer
M Colleoni, F Nole, I Minchella, et al.
Breast Cancer Research and Treatment
|
September 6, 2011
The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause
Jacquie Chirgwin, Zhuoxin Sun, Ian Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?
J Bernhard, B Thürlimann, S F Schmitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 17, 1998
Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making
B F Cole, P Solal-Céligny, R D Gelber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 28, 2004
5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial
A D Roth, R Maibach, N Fazio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 13, 2006
When can a second conservative approach be considered for ipsilateral breast tumour recurrence?
O Gentilini, E Botteri, N Rotmensz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 21, 2007
Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development
Giuseppe Curigliano, Gianluca Spitaleri, Howard J Fingert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 1, 1996
First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88
B Thürlimann, K Beretta, M Bacchi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 26, 1999
Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK)
J Bernhard, M Castiglione-Gertsch, S F Schmitz, et al.
Page
of 76
Search research articles
Search
Showing results (421-430 of 753) with videos related to
Sort By:
Page
of 76
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 1994
Timing of baseline quality of life assessment in an international adjuvant breast cancer trial: its effect on patient self-estimation. The International Breast Cancer Study Group
C Hürny, J Bernhard, A Coates, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 26, 1998
Pre-operative chemotherapy and radiotherapy in breast cancer
M Colleoni, F Nole, I Minchella, et al.
Breast Cancer Research and Treatment
|
September 6, 2011
The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause
Jacquie Chirgwin, Zhuoxin Sun, Ian Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?
J Bernhard, B Thürlimann, S F Schmitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 17, 1998
Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making
B F Cole, P Solal-Céligny, R D Gelber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 28, 2004
5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial
A D Roth, R Maibach, N Fazio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 13, 2006
When can a second conservative approach be considered for ipsilateral breast tumour recurrence?
O Gentilini, E Botteri, N Rotmensz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 21, 2007
Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development
Giuseppe Curigliano, Gianluca Spitaleri, Howard J Fingert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 1, 1996
First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88
B Thürlimann, K Beretta, M Bacchi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 26, 1999
Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK)
J Bernhard, M Castiglione-Gertsch, S F Schmitz, et al.
Page
of 76